Appointment dossier — Peritoneal Sarcoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Peritoneal Sarcoma
- Methotrexate — Animal evidence · 1 positive · PMID 16052545
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT06753136 — Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype (Italy)
- NCT05564377 · Phase 2 — Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (United States)
- NCT07410494 · Phase 1 / Phase 2 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors (China)
- NCT07107633 · Phase 2 — A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor. (China)
- NCT07277413 · Phase 1 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (United States)
- NCT07487168 · Phase 1 — Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors (United States)
- NCT07472140 · Phase 2 / Phase 3 — PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer (Belarus)
- NCT05281471 · Phase 3 — Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (United States)
- NCT04597294 · Phase 3 — Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence (Poland)
- NCT06492070 · Phase 2 — Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers (United States)
- NCT06313801 · Phase 2 — Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions (Russia)
- NCT07480954 · Phase 1 / Phase 2 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) (China)
- NCT05080556 · Phase 2 — Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer (United Kingdom)
- NCT06890338 · Phase 2 — A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. (United States)
- NCT05983276 · Phase 2 — Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer (United States)
- NCT05887609 · Phase 2 — An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib (United States)
- NCT07658196 · Phase 1 — TLR9 Immunotherapy for Peritoneal Carcinomatosis (United States)
- NCT02012699 — Integrated Cancer Repository for Cancer Research (United States)
Most-relevant first: trials that name Peritoneal Sarcoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT06753136), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?